Serum cholinesterase may independently predict prognosis in non-small-cell lung cancer

Abstract

Background Serum cholinesterase (ChE) was found to be involved in cancer initiation and progression. However, the survival association between serum ChE and non-small cell lung cancer (NSCLC) has not been extensively discussed. In the present study, we aim to elevate the role of ChE in overall survival (OS) of NSCLC patients. Methods A total of 961 histologically confirmed NSCLC patients diagnosed between 2013 and 2018 in a provincial cancer hospital in southwestern China were retrospectively selected. Relevant information, such as histological type, clinical stage, chemotherapy, smoking status, body mass index (BMI), important serum indicators (albumin, neutrophil-to-lymphocyte ratio, ChE), date of death of the patients was extracted from the computerized hospital information system. Univariate and multivariate Cox proportional hazards models were used to determine the association between baseline serum ChE measured at the diagnosis and the OS of NSCLC patients. Results The median of baseline ChE (7700 units/liter) was used as a cut-off to dichotomize NSCLC patients. After controlling for possible confounding factors, serum ChE at diagnosis was significantly associated with OS of NSCLC: patients with higher level of ChE were observed a better prognosis (hazard ratio, HR: 0.77, 95% CI: 0.67–0.93, p = 0.006). Subgroup analysis revealed significant ChE-OS association for NSCLC patients: with lower systemic inflammation level (baseline NLR < 2.95, HR: 0.71, 95% CI: 0.56–0.89, p = 0.003), of adenocarcinoma (HR: 0.66, 95% CI: 0.54–0.80, p < 0.001), in advanced stage (HR: 0.77, 95% CI: 0.66–0.92, p < 0.01), and received chemotherapy (HR: 0.75, 95% CI: 0.59–0.96, p < 0.02). Conclusion Baseline ChE may have independent prognostic value for NSCLC patients. Longitudinal studies should be performed to corroborate this finding.

Baseline Serum Cholinesterase Levels Predict the Outcome of HIV-Related Diffuse Large B-Cell Lymphoma

“…Patients with malignancy often receive high-dose chemotherapy, experience weight loss and exhibit malnutrition, which can affect liver synthetic function, including CHE production. Serum CHE has been reported to be a prognostic factor in several solid cancers [8,12] .…”

“…Serum cholinesterase (CHE), as a reliable indicator of liver synthetic function, is closely linked to conditions such as hepatic impairment, malnutrition, heart failure, and progressive systemic in ammation [7] . Recent studies have shown that low serum CHE levels are associated with poor prognosis and decreased chemotherapy effectiveness in various solid cancers, such as gastric cancer [8] , prostate cancer [9] , pancreatic cancer [10] , colorectal cancer [11] , and non-small cell lung cancer [12] , regardless of hepatic involvement.…”

METTL3-mediated m6A modification enhances ZDHHC16 expression in nonsmall- cell lung cancer patients, attenuating ferroptosis by suppressing CREB ubiquitination

“…The 5-year survival rate for lung cancer patients is approximately 4-17%, depending on the stage and region [24]. Considering the different subtypes of lung cancer, targeted therapy is also increasingly used in the personalized treatment of patients [25]. Based on a large number of studies, established risk factors for NSCLC may affect the expression levels of lncRNA in NSCLC tissues and cell lines, thereby affecting the occurrence, development and other malignant phenotypes of NSCLC [25].…”

Construction of 2DE-Patterns of Plasma Proteins: Aspect of Potential Tumor Markers

“…Serum cholinesterase level was significantly lower in the GC group than in the benign gastric disease group [143]. Also, NSCLC patients with a higher level of serum cholinesterase were observed a better prognosis in survival [286]. Its precursor polypeptide chain has 602 AA, where AA 1-28 -the signal peptide and AA 29-602 -cholinesterase (pI/Mw: 6.33/65084).…”